Chugai first to establish stable cell lines of cancer stem cells
Chugai Pharmaceutical (TYO: 44519), which is majority-owned by Swiss drug major Roche (ROG: SIX), has succeeded for the first time in the world in establishing stable cell lines with the nature of colon cancer stem cells that are thought to be involved in the recurrence/metastasis of cancer.
Chugai discovered that the cancer stem cells change to non-proliferative drug-resistant cells after administration of an anticancer drug and restore their proliferative properties when the administration of the anticancer drug is discontinued. The company also found that an antibody that binds to a protein expressed on these cancer stem cells can inhibit metastases when administered into mice that had been injected with the cancer stem cells. These results were published on the electronic version of STEM CELLS, a US scientific journal, on October 18.
Could lead to new type of cancer drug
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze